MADRIGAL PHARMACEUTICALS, INC.
MDGL · XNASCIK 1157601fmd_0VXTJCDNVR7XCP8XB34WM3AFRVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180 | 958 |
| Cost of revenue | – | – | – | – | – | – | 0 | 0 | 6 | – |
| Gross profit | – | – | – | – | – | – | 0 | 0 | 174 | – |
| Research and development | 16 | 24 | 25 | 72 | 185 | 205 | 245 | 272 | 237 | 389 |
| Selling, general and administrative | – | – | – | – | – | – | 48 | 108 | 435 | 814 |
| Total operating expenses | 25 | 32 | 41 | 95 | 207 | 242 | 294 | 380 | 678 | 1,259 |
| Operating income | (25) | (32) | (41) | (95) | (207) | (242) | (294) | (380) | (498) | (300) |
| Interest expense | 1 | – | – | – | 0 | 0 | 4 | 13 | 15 | 22 |
| Interest and investment income | – | – | – | – | – | 0 | 2 | 20 | 47 | 37 |
| Other non-operating income (expense) | – | – | – | – | – | – | – | 0 | 0 | (0) |
| Income before taxes | – | – | – | – | – | – | – | (374) | (466) | (288) |
| Income tax expense | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (374) | (466) | (288) |
| Net income | (26) | (31) | (33) | (84) | (202) | (242) | (295) | (374) | (466) | (288) |
| Net income to common shareholders | (26) | (31) | – | – | – | – | – | – | – | – |